Everyone Wants to Kill the Generic Drug Loophole - Except Drug Makers and Some GOP Leaders
- Boston Globe
What’s Harder Than Making Copycat Biotech Drugs? Selling Them
- Bloomberg
Biosimilars Can Bend the Drug Cost Curve, but Only if Patients Have Access
- Morning Consult
Biosimilar Makers To Congress: Time To Act On REMS Legislation
- Biosimilar Development
The Edison of Medicine
- Harvard Business Review
FDA proposal on biotech drugs sparks criticism
- The Hill Extra
Three Times a Charm
- BioCentury Innovations
Here are 13 local cancer biotechs hoping to make waves next month
- Boston Business Journal
Biosimilars Council Announces 2016 Board of Directors
- Generic Pharmaceutical Association
Implications Of Biosimilars In 2016
- Biosimilar Development
Momenta Pharmaceuticals: How To Unlock The "Black Box" Of Biosimilars
- Biosimilar Development
Globe 100: Recipe for success at Momenta
- The Boston Globe
How the launch of Glatopa transforms Momenta from a 'one-trick pony'
- Boston Business Journal
First generic multiple sclerosis drug, made in Cambridge, launches
- Boston Business Journal
Momenta Applauds FDA Denial of Citizen Petition Requesting FDA Mandate of Information Sharing in Biosimilars Review Process
- Momenta Media Advisory
Last Updated 3/28/2018